AbbVie Shares Pull Back After Six-Session Rally
AbbVie stock slipped Friday, snapping a six-session winning streak as investors paused after a sustained run-up.
AbbVie shares retreated Friday, ending a six-consecutive-session winning streak that had carried the pharmaceutical giant's stock steadily higher. The pullback marked a natural pause in momentum after what had been an unusually consistent stretch of daily gains for the drugmaker.
The six-session advance had positioned AbbVie among the more resilient large-cap healthcare names during the run, drawing attention from investors tracking sector performance. A single-day decline following such a streak is not uncommon, as traders often lock in profits after extended directional moves.
Read more Tech Stocks Climb Tuesday as Sector ETF Leads Afternoon Rally →
AbbVie, best known for blockbuster drugs including Skyrizi and Rinvoq — which have helped offset the long-anticipated revenue erosion from Humira's loss of exclusivity — has remained a closely watched name in pharmaceutical circles. The stock's recent winning run reflected broader investor confidence in the company's ability to sustain growth through its diversified drug portfolio.
While the source did not specify the magnitude of Friday's decline or cite a particular catalyst, the reversal underscores the inherent volatility that follows sharp short-term rallies, even for blue-chip healthcare stocks. Analysts and income-focused investors continue to monitor AbbVie given its reputation as a consistent dividend payer in the sector.
Continue reading at SeekingAlpha.
